The Past, Today, and the Future of Human Papilloma Virus Vaccines

@inproceedings{Kara2011ThePT,
  title={The Past, Today, and the Future of Human Papilloma Virus Vaccines},
  author={Mustafa Cemil Kara and Mehmet Murat Balcı and Neziha Yilmaz},
  year={2011}
}
Human papilloma virus (HPV) is the most common sexually transmitted viral infection. The clinical spectrum of disease ranges from asymptomatic infection, to benign warts (primarily caused by low-risk HPV genotypes 6 and 11) to invasive malignancy. Over 70% of cervical cancer associated with the high-risk genotypes 16 and 18. According to the GLOBOCAN 2002 investigation which is held by International Agency for Research on Cancer the cervical cancer incidence in Turkey is 4.5 in 100.000. It was… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 27 REFERENCES

Immunogenicity and safety of the HPV 16/18 ASo4 adjuvanted vaccine up to 7.3 years

ND Carvalho, CR Martins, J Teixeira
  • 25th International Papillomavirus Conference and Clinical Wokshop,
  • 2009
VIEW 2 EXCERPTS

Immunobiology of HPV and HPV vaccines.

  • Gynecologic oncology
  • 2008
VIEW 3 EXCERPTS

Jinekolojik hastalarda yaflam kalitesi

G Pinar, L Algier, M Colak, A. Ayhan
  • UHOD
  • 2008
VIEW 1 EXCERPT

Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives.

  • Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • 2007
VIEW 2 EXCERPTS

Proof of Principle Study Investigators. Quadrivalent vaccine against human papillomavirus to prevent high grade cervical lesions

LA Koutsky, KA Ault, CM Wheeler
  • N Engl J Med
  • 2007